-
Mashup Score: 0#ASCO23 - 9 month(s) ago
Catch up with our live Twitter coverage from the American Society of Clinical Oncology (#ASCO23) Annual Congress.
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
During the 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings), the AML Hub was pleased to speak with Charles Craddock, Queen Elizabeth Hospital Birmingham, Birmingham, UK. We asked, What does the FIGARO trial reveal about predictors of outcome post-transplant.
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
👀 Monday Re-watch: During #Tandem22, the #AMLHub was pleased to speak with Charles Craddock, Queen Elizabeth Hospital Birmingham. We asked, What does the FIGARO trial reveal about predictors of outcome post-transplant. #AMLsm 👇 https://t.co/ILA3hAjyio https://t.co/12ro4PXsze
-
-
Mashup Score: 4MRD in AML: Prognosis, treatment, and surrogate endpoints - 2 year(s) ago
In recent years, the prognostic value of measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) has been established, and early evidence suggests that MRD analysis may help to guide and personalize treatment decisions.
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🔔 In case you missed it! At the #LLMCongress2021, @RolandBWalter, @fredhutch, provided an update on the status of MRD in the acute myeloid #leukemia setting. 🔎 Take a look at the #AMLHub summary here: 👉 https://t.co/C0Y8a0J6Yl 👈 #AML #leusm #AMLsm https://t.co/sEO93CsUE4
-
-
Mashup Score: 1A new method for developing a consensus guideline in AML - 2 year(s) ago
The AML Hub was pleased to speak with Tom Coats, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK. We asked, What is the new method for developing a consensus guideline in AML.
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🔔In case you missed it! 📹 The #AMLHub spoke with Tom Coats, @RDEhospitals. We asked, What is the new method for developing a consensus guideline in #AML? 👉 https://t.co/eg5srZqTIs 👈 #leusm #leukemia https://t.co/foaMfmgQj0
-
-
Mashup Score: 1
During Lymphoma, Leukemia & Myeloma Congress 2021, the AML Hub was pleased to speak to Koen van Besien, NewYork-Presbyterian Hospital, New York, US. We asked, How do you incorporate measurable residual disease (MRD) into treatment decision-making in clinical practice?
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
⏰Catch up with this! 📹During #LLMCongress2021, the #AMLHub was pleased to speak to @kvbesien, @nyphospital. We asked, How do you incorporate MRD into treatment decision-making in clinical practice? 👉 https://t.co/hKlCsdsPq8 👈 #leusm #AMLsm #AML #leukemia https://t.co/ziLLlJeTlT
-
-
Mashup Score: 3
Gavriilaki begins by discussing a study presented at EBMT 2022 that explored outcomes of fludarabine + treosulfan, which followed on from previous studies exploring treosulfan. Gavriilaki details the study design and patient population, explaining which comparative therapies were used and why. Finally, Gavriilaki outlines different studies presented at EBMT covering fludarabine combinations for…
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
💊During #EBMT22, the #AMLHub spoke with @elenicelli, George Papanikolaou General Hospital of Thessaloniki. We asked, How are new fludarabine conditioning combinations impacting transplant outcomes? 🎧 https://t.co/w3PCi6uSAL 🎧 #AMLsm #leusm #leukemia #AML @SNForg
-
-
Mashup Score: 1
During the 63rd ASH Annual Meeting and Exposition, the AML Hub was pleased to speak with Curtis Lachowiez, MD Anderson Cancer Center, Houston, US. We asked, How can venetoclax combinations be used in preparation for transplant? Lachowiez begins by giving background on venetoclax and recent studies around it.
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📹 In case you missed it! 💉 During #ASH2021, the #AMLHub was pleased to speak with @CLachowiez, @MDAndersonNews. We asked, How can venetoclax combinations be used in preparation for transplant? 👉 https://t.co/0mlTnAZSBO 👈 #leusm #leukemia #AMLsm
-
-
Mashup Score: 1MRD-AML, is RIC enough? - 2 year(s) ago
During The 6th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2021), the AML Hub was pleased to speak with Charles Craddock, Queen Elizabeth Hospital, Birmingham, UK. We asked, Measurable residual disease (MRD)- AML, is a reduced intensity conditioning regimen enough?
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
👀 Have you seen this? The #AMLhub was pleased to speak with Charles Craddock, @qehbhaml. We asked, MRD- #AML, is a reduced intensity conditioning regimen enough? 👉 https://t.co/YhesnbiwYc 👈 @COSTEMCongress #leusm #AMLsm #leukemia #COSTEM2021
-
-
Mashup Score: 1Which AML patients benefit most from treatment with CPX-351? - 2 year(s) ago
The AML Hub was pleased to speak with Jeffrey E. Lancet, Moffitt Cancer Center, Tampa, US. We asked, Which AML patients benefit most from treatment with CPX-351?
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📹The #AMLHub was pleased to speak with Jeffrey E. Lancet, @MoffittNews. We asked, Which #AML patients benefit most from treatment with CPX-351? 👉 https://t.co/kEYSYBQhcG 👈 #leusm #AMLsm #leukemia https://t.co/bqMZg1iiDf
-
-
Mashup Score: 0What does the first-line data for polatuzumab vedotin tell us about its role in R/R DLBCL? - 2 year(s) ago
During the 63rd ASH Annual Meeting and Exposition, the Lymphoma Hub was pleased to speak with Gilles Salles, Memorial Sloane Kettering Cancer Center, New York, US. We asked, What does the first-line data for polatuzumab vedotin tell us about its role in R/R DLBCL?
Source: lymphomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📹 During #ASH2021, the #AMLHub was pleased to speak with @gilles_salles, @sloan_kettering. We asked, What does the first-line data for polatuzumab vedotin tell us about its role in R/R #DLBCL? 👉 https://t.co/MJ59KPNodz 👈 #lymsm #lymphoma https://t.co/KVsXCL2EQ4
-
📢 #ASCO23 | In case you missed our live coverage from ASCO 2023, you can catch up below. 👉 https://t.co/fHKkT8DOIy #AMLHub #AMLsm #acutemyeloidleukemia @ASCO https://t.co/fIdH1YJRMV